Dexmedetomidine alleviates the pro-tumor activity of perioperative stress in tumor-bearing mice: an alternative approach of psycho-physiological intervention.

Patients treated with dexmedetomidine showed a trend toward increased overall and disease-free survival: 1-year overall survival, 96.4% vs. 88.9%; 2-year overall survival, 89.3% vs. 74.1%; 3-year overall survival, 89.3% vs. 70.4%; and 5-year overall survival, 78.6% vs. 59.3% [ 27 ].

also in 53,322 other papers